Innovation.  That’s what we’re about, too.

Tomorrow, Thalocan Research Innovations CEO Eric Zudak begins four days at AAD innovation Academy 2026 – packed with the latest breakthroughs in dermatology, cutting-edge clinical insights and meaningful networking moments.

Here at TRI we share this mindset of creating and sharing innovative and state-of-the-art technologies to assist physicians, trialists and all of those who work to improve the assessment of dermatological diseases.

Whether it’s our:
LAMA (Lesion Area Mapping Assistant) – A cloud-based solution for enhancing lesion assessment in dermatologic clinical trials.

TRICOA (Thalocan Clinical Outcomes Assessment) The first eCOA designed to meet the complex requirements of dermatology scales, scoring and outcomes.

TAVOS (Thalocan Assessment and Validation Online System) built to expedite the time and labor-intensive process of developing and validating measurement endpoints and severity scales.

…or our standard and customized Thalocan Training Library and Learning Lab, TRI applauds AAD for sharing and celebrating innovation.

We’ll see you there.  If we miss you, learn more at www.thalocan.com